ALT
Price
$3.92
Change
-$0.01 (-0.25%)
Updated
Oct 8, 04:59 PM (EDT)
Capitalization
346.85M
34 days until earnings call
CDXS
Price
$2.65
Change
+$0.09 (+3.52%)
Updated
Oct 8, 04:59 PM (EDT)
Capitalization
231.08M
22 days until earnings call
Interact to see
Advertisement

ALT vs CDXS

Header iconALT vs CDXS Comparison
Open Charts ALT vs CDXSBanner chart's image
Altimmune
Price$3.92
Change-$0.01 (-0.25%)
Volume$111.94K
Capitalization346.85M
Codexis
Price$2.65
Change+$0.09 (+3.52%)
Volume$4.19K
Capitalization231.08M
ALT vs CDXS Comparison Chart in %
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. CDXS commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and CDXS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (ALT: $3.93 vs. CDXS: $2.56)
Brand notoriety: ALT and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 69% vs. CDXS: 43%
Market capitalization -- ALT: $346.85M vs. CDXS: $231.08M
ALT [@Biotechnology] is valued at $346.85M. CDXS’s [@Biotechnology] market capitalization is $231.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXS is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 2 bearish.
  • CDXS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than CDXS.

Price Growth

ALT (@Biotechnology) experienced а +4.24% price change this week, while CDXS (@Biotechnology) price change was +4.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.11%. For the same industry, the average monthly price growth was +19.03%, and the average quarterly price growth was +87.04%.

Reported Earning Dates

ALT is expected to report earnings on Nov 11, 2025.

CDXS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+9.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($347M) has a higher market cap than CDXS($231M). ALT (-45.492) and CDXS (-46.331) have similar YTD gains . CDXS has higher annual earnings (EBITDA): -52.78M vs. ALT (-88.03M). ALT has more cash in the bank: 183M vs. CDXS (66.3M). ALT has less debt than CDXS: ALT (15.8M) vs CDXS (69M). CDXS has higher revenues than ALT: CDXS (57.2M) vs ALT (20K).
ALTCDXSALT / CDXS
Capitalization347M231M150%
EBITDA-88.03M-52.78M167%
Gain YTD-45.492-46.33198%
P/E RatioN/AN/A-
Revenue20K57.2M0%
Total Cash183M66.3M276%
Total Debt15.8M69M23%
FUNDAMENTALS RATINGS
ALT vs CDXS: Fundamental Ratings
ALT
CDXS
OUTLOOK RATING
1..100
1418
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6352
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (34) in the Chemicals Specialty industry is somewhat better than the same rating for ALT (96) in the Miscellaneous Commercial Services industry. This means that CDXS’s stock grew somewhat faster than ALT’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that CDXS’s stock grew similarly to ALT’s over the last 12 months.

ALT's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that ALT’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's Price Growth Rating (52) in the Chemicals Specialty industry is in the same range as ALT (63) in the Miscellaneous Commercial Services industry. This means that CDXS’s stock grew similarly to ALT’s over the last 12 months.

CDXS's P/E Growth Rating (100) in the Chemicals Specialty industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that CDXS’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTCDXS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OASMY0.02N/A
N/A
VIVESTO AB
SQNNY34.98N/A
N/A
Square Enix Co., Ltd.
LNDAF1.58N/A
N/A
LINEA DIRECTA ASEGURADORA SA
NEMCL84.17N/A
N/A
Newmont Corporation
TLGRF0.28-0.01
-3.51%
Talga Group Ltd.

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-4.83%
DNLI - CDXS
50%
Loosely correlated
-2.10%
PRAX - CDXS
49%
Loosely correlated
+2.08%
BEAM - CDXS
48%
Loosely correlated
-2.94%
CRSP - CDXS
46%
Loosely correlated
+0.61%
RXRX - CDXS
45%
Loosely correlated
-5.42%
More